Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering.
Immix is developing a novel class of Tissue-Specific Therapeutics ("TSTx") in oncology and inflammation. Its lead asset, IMX-110, is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer. IMX-110 is currently in Phase 1b/2a trials for solid tumors in the US and Australia.
The Los Angeles, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol IMMX. Immix Biopharma filed confidentially on July 20, 2021. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
